GE HealthCare to Buy Sofie Biosciences for $945 Million, Adding U.S. PET Tracer Network
Sofie joins GE HealthCare's diagnostics unit in a $945 million cash deal that adds U.S. PET manufacturing and FAPI-74 rights.
Sofie joins GE HealthCare's diagnostics unit in a $945 million cash deal that adds U.S. PET manufacturing and FAPI-74 rights.
GE HealthCare is considering a deal worth up to $1 billion for Sofie Biosciences, which makes radiopharmaceuticals used in cancer PET scans.
GE HealthCare posts record 11.1% order growth and $5.3B revenue in Q2 2026, beating estimates. Stock jumps as it reviews Patient Care unit sale.
Lantheus licenses PYLARIFY, a leading PSMA PET imaging agent for prostate cancer, exclusively to GE HealthCare for development, manufacturing, and sales in Japan, a key international market.